This research study is testing a drug called remternetug to see if it can help people who have a high chance of getting early-onset Alzheimer's disease (AD) due to genetic mutations. Alzheimer's disease is a brain disorder that affects memory and thinking skills. The study will check if the drug can prevent or reduce the build-up of a protein called amyloid beta (Aβ) in the brain, which is linked to AD. Participants will be people who carry certain gene mutations but do not yet show symptoms. The study will involve brain scans, blood tests, and other checks to track how the drug works and its safety.

• Study Length: Participation may last several years, with regular visits for tests and assessments.
• Eligibility: Participants must be adults with specific gene mutations and no AD symptoms.
• Potential Risks: Includes side effects from the drug and discomfort from tests like brain scans and blood draws.